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Summary
The abnormality in the gene coding for the 13-hexosaminidase a subunit was analyzed in a non-Jewish pa-
tient with clinically typical infantile Tay-Sachs disease. The family was Catholic, and the father and the
mother were of Irish and German descent, respectively. A hitherto undescribed single nucleotide transver-
sion was found within exon 11 (G1260--IC; Trp420-_'Cys). The coding sequence was otherwise entirely nor-
mal. Expression in the COS I cell system confirmed that the mutant gene does not produce functional en-
zyme protein. The mutation can be identified rapidly and reliably because it abolishes one of the two KpnI
sites in the coding sequence. The patient was a compound heterozygote with one allele carrying this muta-
tion. The nature of the abnormality in the other allele remains unidentified. Examination of genomic
DNA from the parents demonstrated that this "Kpn mutation" was inherited from the maternal side of the
family.
Introduction
Normal catabolism ofGM2-ganglioside requires three
distinct protein components -the a and 0i subunits of
13-hexosaminidase and the GM2 activator protein-
each coded by a distinct gene (Sandhoff et al. 1989).
Genetic defects in any of the three genes result in a seri-
ous and nearly always fatal neurological disorder, GM2-
gangliosidosis (Neufeld 1989; Sandhoff et al. 1989).
The classical infantile form of Tay-Sachs disease preva-
lent among Ashkenazi Jews is the prototype of human
GM2-gangliosidosis due to defects in the gene coding
for the jB-hexosaminidase a subunit. Studies of Tay-
Sachs disease entered a new era 5 years ago when a
full-length cDNA coding for the normal human 1-hexos-
aminidase a subunit was isolated and characterized
(Myerowitz et al. 1985), followed soon by character-
Received March 5, 1990; revision received May 1, 1990.
Address for correspondence and reprints: Kunihiko Suzuki, M.D.,
Brain and Development Research Center, CB 7250, University of
North Carolina School of Medicine, Chapel Hill, NC 27599-7250.
o 1990 by The American Society of Human Genetics. All rights reserved.
0002-9297/90/4703-0021$02.00
ization of the normal gene structure (Proia and Soravia
1987). At least 12 gene abnormalities responsible for
clinical disease states are known at this time (Myerowitz
and Hogikyan 1986, 1987; Arpaia et al. 1988; My-
erowitz 1988; Myerowitz and Costigan 1988; Nakano
et al. 1988, 1990; Ohno and Suzuki 1988a, 1988b;
Tanaka et al. 1988, 1990b; Lau and Neufeld 1989;
Navon and Proia 1989; Paw et al. 1989, 1990; Akli
et al. 1990). In 0i subunit defects (Sandhoff disease),
in contrast, only one specific mutation has been reported
that causes a clinical phenotype of juvenile Sandhoff
disease (Nakano and Suzuki 1989), even though the
normal cDNA and genomic clones have been well
characterized (Korneluk et al. 1986; Neote et al. 1988;
Proia 1988). A brief survey suggested extensive genetic
heterogeneity among Sandhoff disease patients
(O'Dowd et al. 1986). A cDNA coding for the normal
human GM2 activator protein has only recently been
cloned (Schroder et al. 1989), and no gene defects in
GM2 activator protein (GM2-gangliosidosis AB vari-
ant) are known at the present time. In the present re-
port, we describe another new I-hexosaminidase a gene
point mutation responsible for a typical infantile clini-
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cal phenotype of Tay-Sachs disease in a non-Jewish in-
fant with ancestors from Ireland, England (probably),
and Germany.
Case History
The patient was the second child in a nonconsan-
guinous marriage of a father of Irish descent and of
a mother believed to be of English and German ances-
try. The family was Catholic on both sides, with no
known Jewish ancestry as far back as 5 generations.
Both sides of the family had resided in the United States
for a few generations. The patient was born by cesar-
ian section after an uncomplicated pregnancy. The birth
weight was 3,550 g, and there were no perinatal or neo-
natal problems. He raised his head at 1 mo, and he rolled
from the prone to the supine position at 3 mo but was
never able to sit up. By 7 mo he had begun to lose spon-
taneous activity. By this time, wandering eye movements
were noted, and any attempt at language ceased. He
was first evaluated at 15 mo at St. Christopher's Hospi-
tal for Children and was noted to have generalized
hypotonia, positive Babinski, absent placing and step-
ping reflexes, hyperacusis, and bilateral cherry-red spots
at the macula. He did not smile, nor did he make eye
contacts. The disease progressed rapidly, and the pa-
tient died at 3 years of age. Extensive enzymatic evalu-
ation of available members of the family was carried
out, and the pedigree, along with the results of screen-
ing tests, is shown in figure 1. The patient's fibroblasts
(GM00527) are available from the NIGMS Human
Genetic Mutant Cell Depository at the Coriell Insti-
tute for Medical Research (Camden, NJ).
Material and Methods
Commercial Material
Bethesda Research Laboratories (Gaithersburg, MD),
Boehringer Mannheim (Indianapolis), Pharmacia (Pis-
cataway, NJ), International Biotechnologies Inc. (New
Haven, CT), and New England Biolab (Beverley, MA)
were the main sources for enzymes, reagents, and other
molecular biological supplies. Radioisotopes were ob-
tained from ICN Radiochemicals (Irvine, CA). 4-Methyl-
umbelliferyl P-N-acetylglucosaminide was purchased
from Sigma Chemical Co. (St. Louis), and 4-methyl-
umbelliferyl 13-N-acetylglucosamine 6-sulfate was from
HSC Research Development Corp. (Toronto). Trans-
formed African green monkey kidney cells (COS I) were
purchased from the American Type Culture Collection
* 0 affected
IO 0 tested carrier
IN] (a) tested normal
D 0 not tested
Figure I Family pedigree. The maternal side of the family is
believed to be primarily English/German in ethnic background, and
the paternal side came from Ireland. Paternal grandmother and mater-
nal grandfather each had nine siblings who were not tested for
1-hexosaminidase activities. The younger sister of the patient (denoted
by the question mark) was tested prenatally by Dr. Eugene Grebner,
Division ofMedical Genetics, ThomasJefferson University (Philadel-
phia) and diagnosed as being not affected. However, her carrier sta-
tus could not be determined conclusively. She has not been retested.
(ATCC) (Rockville, MD). Sources for nonstandard
materials are indicated below.
Fibroblast Cultures
Cultured fibroblasts from the patient (GM00527)
were purchased from the NIGMS Human GeneticMu-
tant Cell Depository (Camden, NJ). Control cell lines
were from the stock cultures in our laboratory.
Enzymatic Assays
I-HexosaminidaseA and B activities were determined
with 4-methylumbelliferyl 3-N-acetylglucosaminide for
differential assays for the A and B isozymes by the heat
inactivation method, and 4-methylumbelliferyl O-N-
acetylglucosamine 6-sulfate was used for direct assess-
ment of the activity of the A isozyme (Suzuki 1987).
The amount of protein was determined essentially by
the method of Lowry et al. (1951).
Cloning and Sequencing of cDNA
The coding sequence for the 1-hexosaminidase a
subunit was examined by obtaining cDNA in two sep-
arate overlapping segments by polymerase chain reac-
tion (PCR) of the total RNA fraction (Saiki et al. 1988;
Sarkar and Sommer 1988). Total RNA was isolated from
fibroblasts from 15 100-mm dishes according to the stan-
dard protocol (Ausubel et al. 1989). Primers used were
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as follows: for upstream PCR,-primer 1 was 5'-TCC-
GAGAGGGGAGACCAGCGG (nucleotides -24 to -4),
and primer 2 was 5'-GGGATACCTGGTCCCCGA
(complementary to nucleotides 795-812); for down-
stream PCR,-primer 3 was 5'-GGGTCCTACAAC-
CCTGTCACC (nucleotides 673-693), and primer 4
was 5'-CCCTCCTCGGTCGGTGGG (complementary
to nucleotides 1593-1610). The size of the amplified
upstream segment was 830 bp, and that of the down-
stream segment was 938 bp. With an approximately
140-bp overlap, the two segments covered the entire pro-
tein coding sequence. The amplified segments were sepa-
rated and purified by low-melting-temperature agarose
electrophoresis.
The amplified upstream segment was digested with
Sacl to generate three fragments (see the restriction map
in Myerowitz et al. 1985). Similarly, the downstream
segment was digested with Sau3AI, which generated
two fragments. These fragments were subcloned into
appropriately digested pUC-18 or pUC-19-plasmid. The
sequences of the inserts were determined in the double-
stranded plasmid by the dideoxy chain termination
method of Sanger et al. (1977), with either the 17-mer
sequencing primer or the 18-mer reverse sequencing
primer (Pharmacia, Piscataway, NJ) and 35S-labeled
dATP (Biggin et al. 1983). The DNA polymerase used
for sequencing was T7 polymerase (Sequenase, U.S. Bio-
chemical Corp., Cleveland). Occasionally, synthetic oli-
gonucleotides complementary to the cDNA sequence
were used, as needed, as primers for sequencing.
Rapid Diagnosis of the Kpn Mutant
Since the mutation abolishes one of the two KpnI
sites within the coding sequence, its existence could be
rapidly determined by restriction analysis of amplified
genomic DNA. A segment of genomic DNA including
the regions of exons 11 and 12 was amplified with the
same primers used earlier in our laboratory for diagno-
sis of the two mutations found in the infantile Jewish
forms of the disease (Tanaka et al. 1990b). The seg-
ment amplified from the normal gene contains two KpnI
sites, while the mutant contains only one KpnI site.
Thus, existence of this mutation could be rapidly tested
by digesting the amplified reaction mixture with KpnI
and examining the products by agarose-gel electropho-
resis.
Expression of the Catalytic Activity in the
COS I Cell System
The catalytic activity of the enzyme protein produced
by the t-hexosaminidase a cDNA clones was expressed
in the COS I cell system. The normal hexosaminidase
a cDNA clone (Myerowitz et al. 1985) was digested
with NarI to leave 60 bases of 5'-untranslated sequence
above the initiation codon and was subcloned into a
eukaryotic expression vector, pSVL. The COS I cells
were transfected by the DEAE-dextran-mediated pro-
cedure (Cullen 1987). jVHexosaminidase activities were
assayed 48 h after transfection with 4-methylumbel-
liferyl ,B-N-acetylglucosaminide and 4-methylumbel-
liferyl 3-N-acetylglucosamine 6-sulfate, as described
above. For expression of the mutant clone, a construct
was made from the normal cDNA already in the pSVL
vector and from the downstream segment of the mu-
tant cDNA. By the unique ApaI site present in the cDNA
but not in the plasmid, the upstream sequence of the
normal cDNA was ligated with the downstream se-
quence of the mutant cDNA at this site, thus generat-
ing the complete mutant coding sequence.
Evaluation of Genetic Status of the Parents
The genomicDNA was prepared from peripheral leu-
kocytes derived from 20 ml of blood from the parents
of the patient. Both the amplification of the relevant
segment of the gene and rapid identification of the Kpn
mutation were carried out as described above.
Results
The assays for ,B-hexosaminidase activities in fibro-
blasts confirmed the diagnosis of hexosaminidase A
deficiency. For five normal controls included and as-
sayed simultaneously, the total hexosaminidase activity
was 125 + 24 nmol/h/mg protein with heat-inacti-
vatable portion of 49% (A) with 4-methylumbelliferyl
N-acetyl-,B-D-glucosaminide as the substrate. The mean
control hexosaminidase A activity assayed directly with
4-methylumbelliferyl N-acetyl-13-D-glucosamine 6-sul-
fate was 14.1 + 5 nmol/h/mg protein. The correspond-
ing values for the patient's fibroblasts were 129 nmol/
h/mg protein with undetectable A components with
the unsulfated substrate and 0.69 nmol/h/mg protein
with the sulfated substrate.
A preliminary Northern blotting experiment on the
poly-A+ RNA fraction showed presence of the ,B-hex-
osaminidase a subunit mRNA of apparently normal
size in the patient's fibroblasts, indicating the feasibil-
ity of approaching the mutation from cDNA (data not
shown). The entire protein coding sequence of the pa-
tient's cDNA was normal except for a single nucleotide
transversion, from normal G to C, at position 1260
within exon 11 (fig. 2). This base change abolishes the
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Figure 2 Portion of sequencing gel of a cDNA segment ob-
tained by PCR of the patient's mRNA and showing the mutation.
This photograph shows the area of the gel covering nucleotides
1247 1271. The C2120 (indicated by an arrow) in this patient should
be C in normal individuals. The sequence shown is the coding strand.
KpnI site present in normal sequence at this location.
The affected nucleotide is the third in the codon and
changes the normal tryptophan at residue 420 to cys-
teine. For each of the two segments of the cDNA ob-
tained by PCR, several subclones were sequenced to as-
sure statistical reliability. All eight clones that included
the region of the mutation had the same transversion,
and all other segments were always normal.
As a means of rapidly and reliably excluding the pos-
sibility of the base transversion being a polymerase er-
ror, absence of the upstream KpnI site was tested by
digesting amplified genomic DNA with KpnI. The
results clearly indicated that the patient was a compound
heterozygote in that (a) the mutation is in only one al-
lele and (b) the other allele is digested normally by KpnI
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Figure 3 Analysis of 0-hexosaminidase a alleles for the Kpn
mutation in the patient and his parents. The sources for genomic
DNA were fibroblasts (for the patient) and leukocytes (for the par-
ents). The diagram depicts the strategy for testing the presence or
absence of the upstream KpnI site. When the amplified segment is
digested by KpnI, the normal allele generates three fragments-90
bp, 270 bp, and 170 bp-because of two KpnI sites within the am-
plified segment, while the lack of the upstream KpnI site in the mu-
tant allele results in only two fragments- 360 bp and 170 bp. Lane
S, Molecular-size standards (+X174 RF DNA; HaeIII digest). Lane
P, Patient. Lane F, Father. Lane M, Mother. Lane N, Normal control.
Numbers on the sides indicate the size (in bp) for the standards (right)
and for the samples (left). Note that the patterns for the patient and
the mother are identical, because they share the Kpn mutant allele
and because the other allele is normal regarding the KpnI sites in
both. On the other hand, the pattern for the father's DNA is identi-
cal with that for the normal control.
nucleotides excluded the following mutations for the
other allele: the two Jewish infantile alleles (the splic-
ing defect and the four-base insertion) and the two B1
variant mutations (C532--T, Argt78-'.Cys; and GS33-e)A,
Argl78-eoHis). Genomic DNA in white blood cells of the
parents were examined similarly. The results showed that
the Kpn mutant allele was inherited from the maternal
side of the family, suggesting a possibility that the muta-
tion may have originated in Germany (fig. 3).
Cos I cells transfected by the pSVL vector containing
the constructed mutant cDNA failed to express the cata-
lytic activity with either the sulfated or the nonsulfated
substrate. The cells transfected by the normal cDNA-
containing vector exhibited high activity of 1-hexos-
aminidase when assayed with the sulfated substrate (fig.
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Figure 4 Expression of catalytic activity in the COS I cells.
The methodological details are described in the text. Substrates
tested are 4-methylumbelliferyl N-acetyl-fo-glucosaminide (,B-GlcNAc),
4-methylumbelliferyl N-acetyl-,B-glucosamine 6-sulfate (13-GlcNAc-
S04), and 4-methylumbelliferyl 3-galactoside (13-Gal) (control). With
either of the ,B-hexosaminidase substrates, the patient's cDNA failed
to increase the enzymatic activities above the endogenous baseline
level. The data are from a representative experiment, and the error
bars indicate SDs for triplicate samples. In three transfection experi-
ments, the interexperimental scatters were generally within 10%.
dase activity measured with unsulfated substrate was
only twice the baseline even when the cells were trans-
fected by normal cDNA. This is because hexosamini-
dase S (aa) which would be generated from the excess
a subunit when the available endogenous subunit is
exhausted to form hexosaminidase A (a) has little ac-
tivity toward the nonsulfated substrate. In any event,
this experiment demonstrated that this patient's point
mutation, Trp420o-Cys, in the ,3-hexosaminidase a
subunit does not generate functional enzyme protein.
Discussion
The classical infantile form of Tay-Sachs disease oc-
curring in the Ashkenazi Jewish population had been
thought to be genetically homogeneous because of both
its high incidence in a specific ethnic group and its
phenotypic uniformity. Even though the prediction has
been proved incorrect, two gene abnormalities appear
to account for most, if not all, of Jewish patients hav-
ing the classical form of the disease (Arpaia et al. 1988;
Myerowitz 1988; Myerowitz and Costigan 1988; Ohno
and Suzuki 1988c). The major deletion at the 5' end
of the gene also appears to account for most patients
with the other ethnically restricted phenotype, which
occurs among French Canadians (Myerowitz and
Hogikyan 1986, 1987). However, genetic complexity
increases enormously in geographically and ethnically
sporadic patients. This was predictable, considering the
large number of possible gene abnormalities that can
inactivate the normal function of the enzyme protein.
Even among clinically typical infantile patients, we
found a unique mutation in a Japanese infant (Nakano
et al. 1990). As expected, compound heterozygosity
is a rule rather than an exception among sporadic non-
consanguinous patients. Of the 11 patients of various
phenotypes whom we have studied in detail, eight were
compound heterozygotes. Of the three homozygous pa-
tients, two were known to be consanguinous, and the
third can be suspected of consanguinity although there
is no positive record, because both parents originated
from the same village in Spain. In most of these com-
pound heterozygous patients, the nature of the abnor-
malities in the other allele is not known. The only ex-
ception is our original patient with the B1 variant form
of the disease (Goldman et al. 1980). In one allele this
patient has one of the two point mutations known to
cause the B1 variant phenotype-namely, mutation
G533--A, Arg178--His-while the other allele has one
of the infantile Jewish alleles-namely, the four-base
insertion in exon 11 (Tanaka et al. 1990b).
The mutation described in the present report adds
another to the growing list of genetic 3-hexosaminidase
a deficiencies. The patient follows the rule for the
majority of sporadic cases; the mutation is unique and
in only one allele. Eight successive clones containing
this region all included the same mutation. Further-
more, a large number of segments from other regions
of the cDNA were always normal in their base sequence.
Thus, it is likely that most of the stable mRNA derives
from this allele, even when due caution regarding pos-
sible bias during PCR is taken into account. Of the six
known mutations which result in substitution of single
amino acids, five involve amino acids that are conserved
between the a and 13 subunits, and, in fact, four ofthem
are in amino acids conserved even in 1-hexosaminidase
of the slime mold, Dictyostelium discoideum (Graham
et al. 1988). The tryptophan residue involved in the
mutation in the present patient is not conserved in ei-
ther the human 13 subunit or the yeast enzyme. Even
though this tryptophan residue may not be function-
ally critical by itself, its substitution with cysteine cre-
ates a possibility of new disulfide bonding and thus an
entirely abnormal three-dimensional structure.
The information on the parents indicates that this
Kpn mutation originated in the family's maternal side,
which is ofGerman descent. This point should be kept
in mind when sporadic cases of infantile Tay-Sachs dis-
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ease are evaluated. It can be easily and quickly screened
for by the absence of one of the two KpnI sites in the
exon sequence.
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